VitaScope

This article was automatically translated into your selected language.

CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trialVIP

Nature Medicine, Published online: 27 August 2026; doi:10.1038/s41591-026-04603-3 In the phase 1 part of the ongoing phase 1/2 COMPARE trial, CD19 CAR T cell treatment of patients with severe, treatment-refractory rheumatoid arthritis was well tolerated with clinical improvement seen in all patients.]]>

Nội dung không phải là chẩn đoán y khoa hay khuyến nghị điều trị. Luôn tham khảo ý kiến bác sĩ.